Zhou et al. [114] found that a PD-L1 inhibitor in combination with a TIM-3, LAG-3, or CTLA-4 inhibitor results in a revitalization of in vitro tumor-infiltrating lymphocyte (TIL) responses in most patients and further enhances its effect compared to PD-L1 monotherapy. This evidence concerns the gene CD274 and neoplasm.